European Medicines Agency Approves Modification to Paediatric Investigation Plan for Emgality and Galcanezumab

Summary

The European Medicines Agency has issued an opinion and decision on a Paediatric Investigation Plan (PIP) for Emgality and Galcanezumab, a modification to an agreed PIP for surgical and medical procedures, following a request from the applicant.